Shots:

• The first patient has been dosed in the P-Ib study evaluating CTX-471 + Merck’s Keytruda in patients with advanced solid tumors i.e., NSCLC, melanoma, SCLC, mesothelioma & HNC that have progressed after treatment with a checkpoint inhibitor
• In the first part of the P-Ib study, CTX-471 was dosed as a monothx. and showed signs of activity in patients with multiple metastatic or LA solid tumors who initially benefited from a checkpoint inhibitor
• CTX-471 is a fully human IgG4 agonistic Ab that binds to a unique membrane-proximal epitope of the CD137 receptor that has a co-stimulatory effect on T-Cells & NK Cells. The P-I dose escalation cohort & expansion study of CTX-471 was found to be well-tolerated

Ref: Compass Therapeutics | Image: Compass Therapeutics